Background: Razupenem ( previously known as PTZ601, PZ-601, SMP-601 or SM-216601) is a novel carbapenem, active against Enterobacteriaceae as well as Gram-positive bacteria including methicillinresistant staphylococci and enterococci.
Introduction
Razupenem (formerly PTZ601, PZ-601, SMP-601 or SM-216601) is a novel b-methyl carbapenem, active against methicillin-resistant staphylococci and enterococci, including many Enterococcus faecium.
1 It also has anti-enterobacterial activity and might be used in settings where these organisms are likely to be present either alone or together with Gram-positive pathogens. On this basis we sought to determine its activity against Enterobacteriaceae with critical resistance mechanisms, including extended-spectrum b-lactamases (ESBLs), derepressed or plasmid-mediated AmpC enzymes and combinations of these mechanisms with porin loss. These types of resistance are all increasing: the rapid spread of ESBLs, particularly CTX-M types, in Europe and Asia has been extensively reviewed, 2 whilst porin-deficient ESBLor AmpC-producing Enterobacter and Klebsiella spp. are increasingly scattered and show some resistance to established carbapenems, particularly ertapenem. 3 
Materials and methods
The Escherichia coli J53, J62 and DH5a transconjugants and transformants with plasmid-mediated b-lactamases (n¼ 21) were described previously, as were the isogenic AmpC and Proteus vulgaris mutant series [17 series comprising 48 organisms with inducible, derepressed (high-level constitutive) and basal (low-level constitutive) chromosomal b-lactamase expression]. 4, 5 Clinical isolates (n¼ 306) with ESBLs or AmpC enzyme were from recent survey collections, 6 or were UK reference submissions. Their resistance mechanisms were categorized by interpretive reading, PCR of b-lactamase genes and, in the case of the ertapenem-resistant porindeficient organisms, by outer membrane protein profiling and sequence analysis of porin genes and their flanking regions. 
Results

E. coli transconjugants
Most broad-spectrum b-lactamases and ESBLs had no effect on the MICs of razupenem or on those of other carbapenems, whereas ESBLs raised the MICs of ceftriaxone and cefepime ( Table 1 ). The sole exception to these generalizations was that the OXA-3 enzyme was associated with a 32-fold rise in the MIC of razupenem, from 0.25 mg/L to 8 mg/L, without a significant effect on the MICs of other carbapenems. Curiously, OXA-2, which differs from OXA-3 by only a single substitution, 8 had no such effect. IMP-1, NMC-A and KPC carbapenemases raised the MICs of all carbapenems, with values of razupenem consistently 16 mg/L.
Chromosomal b-lactamase mutants
The general pattern for razupenem among mutant series varying in expression of AmpC enzymes was: MIC derepressed (CON). MIC inducible. MIC basal (DEF) ( Table 1 ). For Enterobacter cloacae and Citrobacter freundii, the MICs for the derepressed mutants ranged from 4-16 mg/L versus 0.25-2 mg/L for the corresponding AmpC-inducible organisms and 0.06 -1 mg/L for the AmpC-basal mutants. The MIC differentials in relation to the AmpC phenotype were smaller in the Serratia marcescens and Morganella morganii series but followed the same general pattern. For P. vulgaris, which has a class A chromosomal b-lactamase, there was little relationship between b-lactamase expression and MICs, which were consistently ,1 mg/L.
Among the comparators, ertapenem and cefepime generally had slightly less activity against AmpC-derepressed mutants than against the AmpC-inducible and -basal organisms, nevertheless their MICs for the derepressed strains never exceeded 1-2 mg/L; ceftriaxone and piperacillin/tazobactam had classical 'labile weak 
Continued inducer' behaviour, with MICs for AmpC-derepressed mutants considerably higher than for the AmpC-inducible and -basal organisms. Imipenem, a strong inducer with minimal liability, had equal activity against inducible and derepressed organisms, with slightly greater susceptibility seen for some AmpC-basal organisms.
Clinical isolates with b-lactamases
MIC distributions for clinical isolates with AmpC, ESBL and K1 enzymes are shown in Table 2 . The Enterobacter and Klebsiella spp. isolates were graded as either ertapenemsusceptible or -non-susceptible, based on previous data. Non-susceptibility to ertapenem was contingent on the combination of outer membrane impermeability and AmpC (Enterobacter spp.), or outer membrane impermeability and an ESBL (Klebsiella spp.), not upon carbapenemases. Among the ertapenem-susceptible ESBL producers, .90% of the E. coli and 65% of the Klebsiella isolates were inhibited by razupenem at 0.5-2 mg/L, although values as high as 8 mg/L were recorded for a few isolates of these species. MIC values for ESBL-producing Enterobacter spp. were higher, mostly falling between 1 and 8 mg/L.
MICs for AmpC-hyperproducing strains were higher than for ESBL producers, at 1-8 mg/L for E. coli and 4-16 mg/L for Enterobacter spp. Combinations of ESBL and impermeability in Klebsiella spp. raised the MICs of razupenem to 2-4 mg/L, whereas combinations of impermeability and high-level AmpC in Enterobacter spp. raised MICs to 16-32 mg/L. Imipenem remained active at 4 mg/L against almost all the isolates tested, the exceptions being seven isolates of Enterobacter spp. with impermeability and high-level AmpC (MIC¼8-16 mg/L), with modal MICs 0.12-0.5 mg/L and 1-4 mg/L for the ertapenemsusceptible and -resistant groups, respectively. Ceftriaxone had widely scattered MICs for ertapenem-susceptible ESBLproducing E. coli and Klebsiella spp., but with over half the values 128 mg/L, whilst cefepime had bimodal MIC distributions. AmpC-hyperproducers were mostly resistant to ceftriaxone, but cefepime remained active except against those also lacking porins.
Discussion
Razupenem, which is now in Phase II development, is being investigated primarily for its activity against Gram-positive pathogens, 1 but also has good activity against many Enterobacteriaceae. As shown here, this activity is little affected by ESBLs, with near-identical MICs for recipient E. coli strains and their ESBL-producing derivatives, and with the retention of good activity against ESBL-producing clinical isolates of E. coli and Klebsiella spp. Even the combination of outer membrane impermeability with an ESBL had little effect on its activity. In this respect razupenem resembled imipenem, whereas ertapenem was more affected. Kinetic studies show that k cat values of ESBLs for PTZ 601 are as low as those for imipenem. 9 By contrast, razupenem seemed relatively more affected than imipenem or ertapenem by AmpC enzymes. Thus: (i) both inducible and, more especially, derepressed AmpC enzymes gave some protection, particularly in the Enterobacter spp. and C. freundii mutant series; (ii) AmpC-producing E. coli were less susceptible than those with ESBLs, with modal MICs of 2 and 0.5 mg/L, respectively; (iii) most Enterobacter spp., with inducible AmpC, were less susceptible than E. coli or Klebsiella spp; 1 (iv) most AmpC-derepressed Enterobacter spp. isolates and mutants had low-level resistance, with MICs of 8 mg/L; and (v) the combination of derepressed AmpC and impermeability gave unequivocal resistance, with MICs of 16 -32 mg/L. The weaker activity of razupenem against Enterobacter spp. compared with other Enterobacteriaceae has been remarked on by others, and the present data on AmpC interactions provide a plausible explanation, although kinetic studies have not revealed significant lability. 10 Carbapenemase producers were not considered in detail; however, E. coli constructs with the IMP-1 (class B) and either NMC-A or KPC-3 (class A) enzymes were consistently resistant, with MICs 16 mg/L, suggesting that razupenem remains vulnerable to these enzymes. 
